Specialized Anemia Treatment Solutions for Niche Patient Populations
Legal Citation
Summary of the Inventive Concept
The present disclosure relates to novel compositions and methods for treating anemia in specific patient populations with unique needs, such as those with chronic kidney disease, residing in high-altitude regions, with a history of chemotherapy, or with limited access to medical resources.
Background and Problem Solved
The original patent disclosed the use of HIF prolyl hydroxylase inhibitor compounds for treating anemia. However, these compounds may not be effective or suitable for all patient populations, particularly those with specific challenges or limitations. The present inventive concept addresses this limitation by providing specialized anemia treatment solutions tailored to the needs of niche patient populations.
Detailed Description of the Inventive Concept
The new inventive concept encompasses a range of specialized anemia treatment solutions, including systems, methods, and compositions adapted for specific patient populations. For example, a system for treating anemia in patients with chronic kidney disease may include a HIF prolyl hydroxylase inhibitor compound and a monitoring device for tracking hemoglobin levels, with the system configured to adjust the dosage of the compound based on the tracked hemoglobin levels. Similarly, a method for preventing anemia in patients residing in high-altitude regions may involve administering a pharmaceutically effective amount of a HIF prolyl hydroxylase inhibitor compound, with the compound formulated to provide a rapid increase in hemoglobin levels.
Novelty and Inventive Step
The new claims introduce novel and non-obvious features, such as the integration of monitoring devices, portable dispensers, and user interfaces, which provide a significant improvement over the original patent. These features enable more effective and targeted treatment of anemia in niche patient populations, addressing specific challenges and limitations not addressed by the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include variations in the type of HIF prolyl hydroxylase inhibitor compound used, the formulation and dosage of the compound, and the specific components and features of the systems and methods. For example, a system for treating anemia in patients with limited access to medical resources may utilize a simplified, low-cost dispenser and user interface, while a method for treating anemia in patients with a genetic predisposition to anemia may involve a sustained-release formulation of the compound.
Potential Commercial Applications and Market
The present inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in markets focused on niche patient populations. The specialized anemia treatment solutions may be marketed to healthcare providers, hospitals, and clinics serving these patient populations, offering a competitive advantage over existing anemia treatments.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical compositions and methods for treating anemia, specifically focusing on HIF prolyl hydroxylase inhibitor compounds and their applications in managing hemoglobin levels across various patient populations
Person of Ordinary Skill (PHOSITA) Profile
A medical researcher or pharmaceutical scientist with expertise in hematology, pharmacology, and drug delivery systems, possessing knowledge of HIF pathway modulation and anemia treatment strategies
Obviousness Rationale
A person of ordinary skill would recognize that the PTD represents predictable variations of the source patent's core technology by applying known monitoring and delivery techniques to the established HIF prolyl hydroxylase inhibitor treatment approach. The variations demonstrate standard design modifications that extend the original patent's treatment method to specific patient populations using well-understood pharmaceutical engineering principles. These adaptations represent incremental improvements that would be apparent to a skilled practitioner seeking to optimize anemia treatment across diverse clinical contexts.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,543 |
|---|---|
| Title | Compositions and methods for treating anemia |
| Assignee(s) | Akebia Therapeutics, Inc. |